Dr. Mark Gilbert on Genetics as a Predictive Tool for Treatment Response in Brain Cancer
Mark Gilbert, MD, neuro-oncologist, chief of neuro-oncology, National Institute of Health, discusses predicting how a patient's brain tumor might act and respond to treatment based on their genetics.
Mark Gilbert, MD, neuro-oncologist, chief of neuro-oncology, National Institute of Health, discusses predicting how a patient's brain tumor might act and respond to treatment based on their genetics. Gilbert says one way an oncologist might be able to predict these factors is looking at a patient's nucleotides in their DNA. He says these polymorphisms can reveal different types of enzyme activity, which in turn can potentially allow oncologists to guess more accurately at how a treatment might impact a patient.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
